Merck, in latest COVID-19 setback, scraps one drug and pins hopes on another
Bio Pharma Dive
APRIL 15, 2021
The decision to end development of a medicine acquired in a $425 million deal last November is another disappointment for Merck's coronavirus effort, which once involved multiple drugs and vaccines.
Let's personalize your content